Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 7
Submit an article Journal homepage
265
Views
30
CrossRef citations to date
0
Altmetric
Drug Evaluations

Sustained-release fampridine for multiple sclerosis

Christopher T Bever Jr University of Maryland Hospital, Department of Neurology, Room N4W46, 22 South Greene Street, Baltimore, Maryland 21201, USA +1 410 605 7130; +1 410 605 7929; [email protected]
&
Susan IV Judge University of Maryland Hospital, Department of Neurology, Room N4W46, 22 South Greene Street, Baltimore, Maryland 21201, USA +1 410 605 7130; +1 410 605 7929; [email protected]
Pages 1013-1024 | Published online: 24 Jun 2009

Bibliography

  • Anonymous. Business wire: Acorda Therapeutics submits new drug application for Fampridine SR for improvement of walking ability in people with multiple sclerosis. Wall Street Jounal Online, 2 February 2009. Available from: http://online.wsj.com/article/ PR-CO-20090202-901621.html? mod = wsjcrmain [Cited 25 Feb 2009]
  • Compston A, Confavreux C. The distribution of multiple sclerosis. In: Compston A, editor, McAlpine's multiple sclerosis. 4th edition. Philadelphia, PA: Churchill Livingstone; 2005. p. 71-111
  • Burton JM, Bell CM, Walker SE, O'Connor PW. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008;71:1833-4
  • van Diemen HAM, Polman CH, Koetsier JC, et al. 4-aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16:195-204
  • Bever CT, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double blind, concentration controlled crossover trial. Neurology 1994;44:1054-9
  • Bever CT, Young D, Tierney D, et al. The pharmacokinetics and tolerability of a slow-release formulation of 4-aminopyridine in multiple sclerosis. Neurology 1995;45(Suppl):A351
  • Cohen R. 4-Aminopyridine. In: Pharmacy Compounding Advisory Committee transcript, 6 May 1999, 165-261. Available from: www.fda.gov/ohrms/dockets/ac/99/transcpt/3513t1.rtf [Cited 25 Feb 2009]
  • Available from: www.acorda.com [Cited 23 Feb 2009]
  • Frohman E, Racke M, Raine C. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006;354:942-55
  • Confavreux C, Compston A. The natural history of multiple sclerosis. In: Compston A, editor. McAlpine's multiple sclerosis. 4th edition. Philadelphia, PA: Churchill Livingstone; 2005. p. 183-269
  • Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-7
  • Mcdonald I, Compston A. The symptoms and signs of multiple sclerosis. In: Compston A, editor, McAlpine's Multiple Sclerosis: Fourth Edition. Churchill Livingstone Elsevier, Philadelphia, PA, USA; 2005. p. 287-346
  • Noseworthy J, Miller D, Compston A. The treatment of symptoms in multiple sclerosis and the role of rehabilitation. In: Compston A, editor, McAlpine's Multiple Sclerosis: Fourth Edition, Churchill Livingstone Elsevier, Philadelphia, PA, USA; 2005. p. 701-25
  • Available from: www.sanofiaventis.com; [Accessed 22 February 2008]
  • Judge SIV, Bever CT. Potssium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharm Ther 2006;111:224-59
  • DeGrazio JW, Besser JF, Decino TJ, et al. Use of 4-aminoppyridine to protect ripening corn from blackbirds. J Wildl Mgmt 1971;35:565-9
  • Judge SIV, Yeh JZ, Goolsby JE, et al. Determinants of 4-aminopyridine sensitivity in a human brain Kv1.4 K + channel: Phenylalanine substitutions in leucine heptad repeat region stabilize channel closed state. Mol Pharm 2002;61:913-20
  • Judge SIV, Monteiro MJ, Yeh JZ, Bever CT. Inactivation gating and 4-AP sensitivity in human brain Kv1.4 potassium channel. Brain Res 1999;831:43-54
  • Lai HC, Jan LY. The distribution and targeting of neuronal voltage-gated ion channels. Nat Rev Neurosci 2006;7:548-62
  • Rutecki PA, Labeda FJ, Johnson D. 4-aminopyridine produces epileptiform activity in the hippocampus and enhances synaptic excitation and inhibition. J Neurophysiol 1987;57:1911-24
  • Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-84
  • Lemeignan M, Lechat P. Sur l'action anticurare des aminopyridines. C R Acad Sci Paris Serie D 1967;264:169-72
  • Agoston S, Salt PJ, Erdmann W, et al. Antagonism of ketamine-diazepam anesthesia by 4-aminopyridine in human voluteers. Br J Anesth 1980;52:367-70
  • Molgo J, Lemeignan M, Lechat P. Effects of 4-aminopyridine at the frog neuromuscular junction. J Pharmacol Exp Ther 1977;203:653-63
  • Heuser JE, Reese TS, Dennis MJ, et al. Synatpic vescicle exocytosis captured by quick freezing and correlated with quantal transmitter release. J Cell Biol 1979;81:275-300
  • Glover WE. The aminopyridines. Gen Pharmacol 1982;13:259-85
  • Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-71
  • Smith JP, Waxman SG. The conduction properties of demyelinated and remyelinated axons. In: Waxman SG, editor, Multiple Sclerosis as a Neuronal Disease, Elsevier Academic Press, Amsterdam; 2005. p. 85-100
  • Rasband MN. Potassium channel organization of myelinated and demyelinated axons. In: Waxman SG, editor, Multiple Sclerosis as a Neuronal Disease, Elsevier Academic Press, Amsterdam; 2005. p. 57-67
  • Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989;22:47-52
  • Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian fibers. J Physiol 1981;313:301-15
  • Evenhuis J, Agoston S, Salt PJ, et al. Pharmacokinetics of 4-aminopyridine in human volunteers: a preliminary study using a new GLC method for its estimation. Br J Anesth 1981;53:567-70
  • Hayes KC, Katz MA, Devane JG, et al. Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;31:379-85
  • Uges DRA, Sohn YJ, Greijdanus B, et al. 4-aminopyridine kinetics. Clin Pharmacol Ther 1982;31:587-93
  • Blight AR, Henney HR. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009;31:328-35
  • Segal JL, Hayes KC, Brunnemann SR, et al. Absorption characteristics and tolerability of a slow-release formulation of 4-aminopyridine in patients with chronic spinal cord injury. J Clin Pharmacol 2000;40:402-9
  • Jones HE, Heron JR, Foster DH, et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-62
  • Stefoski D, Davis FA, Faut M, Schauf CL. 4-aminopyridine in patients with multiple sclerosis. Ann Neurol 1987;27:71-5
  • Davis FA, Stefoski D, Schauf CL. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-92
  • Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-8
  • van Diemen HAM, Polman CH, van Dongen MM, et al. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993;116:220-6
  • van Diemen HAM, Polman CH, van Dongen MM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, crossover study. Ann Neurol 1992;32:123-30
  • Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
  • Polman CH, Bertelsmann FW, de Waal, et al. 4-aminopyridine in superior to 3,4 diaminopyridine in the treatment of multiple sclerosis. Arch Neurol 1994;51:1136-9
  • Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis: Long-term efficacy and safety. Arch Neurol 1994;51:292-6
  • Smits RCF, Emmen HH, Bertelsmann FW, et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994;44:1701-5
  • Bever CT, Katz E, Tierney D, Johnson KP. Experience with slow release 4-aminopyridine in multiple sclerosis patients: long term tolerability and safety. J Neuroimmunol 1995;1(Suppl):58
  • Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21
  • Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose ranging study. Mult Scler 2007;13:357-68
  • Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
  • Kryscio RJ. Fampridine for MS responders: clinically relevant or hypothesis generating? Neurology 2008;71:1130-1
  • Goodman AD, Brown T, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial. Lancet 2009;373:732-8
  • Goodman AD, Schwid S, Brown T, et al. Sustained-release fampridine consistently improves walking speed and leg strength in multiple sclerosis: a phase 3 trial. World Congress of Treatment and Research in Multiple Sclerosis, Montreal, 2008, Program, Poster session 3 – Late Breaking News, P909
  • Anonymous. Betaseron. In: Physicians Desk Reference. PDR Staff, editor, 2007, Thompson Health Care Inc., Montvale, NJ, 767-771
  • Hayes KC. Fampridine-SR in multiple sclerosis and spinal cord injury. Expert Rev Neurother 2007;7:1-9
  • Rucker JC. Current treatment of nystagmus. Curr Treat Options Neurol 2005;7:69-77
  • Judge SIV, Lee JM, Bever CT, Hoffman PM. Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehab Res Dev 2006;43:111-22

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.